IDEAS home Printed from https://ideas.repec.org/r/sae/medema/v13y1993i4p322-338.html
   My bibliography  Save this item

Markov Models in Medical Decision Making

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Turgay Ayer & Oguzhan Alagoz & Natasha K. Stout, 2012. "OR Forum---A POMDP Approach to Personalize Mammography Screening Decisions," Operations Research, INFORMS, vol. 60(5), pages 1019-1034, October.
  2. Célia Berchi & Véronique Bouvier & Jean‐Marie Réaud & Guy Launoy, 2004. "Cost‐effectiveness analysis of two strategies for mass screening for colorectal cancer in France," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 227-238, March.
  3. Robert L. Herrick & Steven G. Buchberger & Robert M. Clark & Margaret Kupferle & Regan Murray & Paul Succop, 2012. "A Markov Model To Estimate Salmonella Morbidity, Mortality, Illness Duration, And Cost," Health Economics, John Wiley & Sons, Ltd., vol. 21(10), pages 1169-1182, October.
  4. Jun Li & Benjamin H K Yip & Chichiu Leung & Wankyo Chung & Kin On Kwok & Emily Y Y Chan & Engkiong Yeoh & Puihong Chung, 2018. "Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-18, January.
  5. Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 30(7), pages 575-593, July.
  6. Bärnighausen, Till & Bloom, David E., 2009. ""Conditional scholarships" for HIV/AIDS health workers: Educating and retaining the workforce to provide antiretroviral treatment in sub-Saharan Africa," Social Science & Medicine, Elsevier, vol. 68(3), pages 544-551, February.
  7. K. Cooper & S. Brailsford & R. Davies & J. Raftery, 2006. "A review of health care models for coronary heart disease interventions," Health Care Management Science, Springer, vol. 9(4), pages 311-324, November.
  8. Isabel Barrachina-Martínez & Ana Navarro-Quiles & Marta Ramos & José-Vicente Romero & María-Dolores Roselló & David Vivas-Consuelo, 2020. "Probabilistic Study of the Effect of Anti-Epileptic Drugs Under Uncertainty: Cost-Effectiveness Analysis," Mathematics, MDPI, vol. 8(7), pages 1-19, July.
  9. Afschin Gandjour & Eva-Julia Weyler, 2006. "Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries," Health Care Management Science, Springer, vol. 9(4), pages 359-369, November.
  10. Heß, Michael (Ed.) & Schlieter, Hannes (Ed.), 2014. "Modellierung im Gesundheitswesen: Tagungsband des Workshops im Rahmen der Modellierung 2014," ICB Research Reports 57, University Duisburg-Essen, Institute for Computer Science and Business Information Systems (ICB).
  11. Zixian, Liu & Xin, Ni & Yiliu, Liu & Qinglu, Song & Yukun, Wang, 2011. "Gastric esophageal surgery risk analysis with a fault tree and Markov integrated model," Reliability Engineering and System Safety, Elsevier, vol. 96(12), pages 1591-1600.
  12. Marco Bonetti & Raffaella Piccarreta & Gaia Salford, 2013. "Parametric and Nonparametric Analysis of Life Courses: An Application to Family Formation Patterns," Demography, Springer;Population Association of America (PAA), vol. 50(3), pages 881-902, June.
  13. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
  14. Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
  15. Rowan Iskandar, 2018. "A theoretical foundation for state-transition cohort models in health decision analysis," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-11, December.
  16. Malek Ebadi & Raha Akhavan-Tabatabaei, 2021. "Personalized Cotesting Policies for Cervical Cancer Screening: A POMDP Approach," Mathematics, MDPI, vol. 9(6), pages 1-20, March.
  17. Jonah Popp & John A. Nyman & Xianghua Luo & Jill Bengtson & Katherine Lust & Lawrence An & Jasjit S. Ahluwalia & Janet L. Thomas, 2018. "Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1319-1333, December.
  18. B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich, 2007. "Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 51-57, March.
  19. Felli, James C. & Anderson, Wesley H. & Kremidas, James P. & Ruberg, Stephen J., 2007. "A semi-Markov model for patient progression through clinical trials," European Journal of Operational Research, Elsevier, vol. 176(1), pages 542-549, January.
  20. Turgay Ayer, 2015. "Inverse optimization for assessing emerging technologies in breast cancer screening," Annals of Operations Research, Springer, vol. 230(1), pages 57-85, July.
  21. Michael Frank Mørup & Steven M Kymes & Daniel Oudin Åström, 2020. "A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-10, June.
  22. Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
  23. Franck Maunoury & Christian Farinetto & Stéphane Ruckly & Jeremy Guenezan & Jean-Christophe Lucet & Alain Lepape & Julien Pascal & Bertrand Souweine & Olivier Mimoz & Jean-François Timsit, 2018. "Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-16, May.
  24. Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol, 2005. "Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 112-123, June.
  25. Hossein Ali Afzali & Jonathan Karnon & Jodi Gray, 2012. "A Critical Review of Model-Based Economic Studies of Depression," PharmacoEconomics, Springer, vol. 30(6), pages 461-482, June.
  26. Catherine Lejeune & Kazem Al Zahouri & Marie-Christine Woronoff-Lemsi & Patrick Arveux & Alain Bernard & Christine Binquet & Francis Guillemin, 2005. "Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 203-214, September.
  27. Sarang Deo & Seyed Iravani & Tingting Jiang & Karen Smilowitz & Stephen Samuelson, 2013. "Improving Health Outcomes Through Better Capacity Allocation in a Community-Based Chronic Care Model," Operations Research, INFORMS, vol. 61(6), pages 1277-1294, December.
  28. Hiral Anil Shah & Tim Baker & Carl Otto Schell & August Kuwawenaruwa & Khamis Awadh & Karima Khalid & Angela Kairu & Vincent Were & Edwine Barasa & Peter Baker & Lorna Guinness, 2023. "Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania," PharmacoEconomics - Open, Springer, vol. 7(4), pages 537-552, July.
  29. Gyeyoung Choi & Yujeong Kim & Gyeongseon Shin & SeungJin Bae, 2022. "Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea," IJERPH, MDPI, vol. 19(5), pages 1-14, February.
  30. Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville, 2008. "Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas," PharmacoEconomics, Springer, vol. 26(1), pages 33-44, January.
  31. Emma McManus, 2024. "Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model," PharmacoEconomics - Open, Springer, vol. 8(4), pages 569-583, July.
  32. Laura Delgado-Ortega & Almudena González-Domínguez & Josep María Borrás & Juan Oliva-Moreno & Eva González-Haba & Salomón Menjón & Pedro Pérez & David Vicente & Luis Cordero & Margarita Jiménez & Susa, 2019. "The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 135-147, February.
  33. Patricia Vold Pepper & Douglas K. Owens, 2002. "Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults," Medical Decision Making, , vol. 22(1_suppl), pages 45-57, September.
  34. Weidong Huang & Guoxiang Liu & Xin Zhang & Wenqi Fu & Shu Zheng & Qunhong Wu & Chaojie Liu & Yang Liu & Shanrong Cai & Yanqin Huang, 2014. "Cost-Effectiveness of Colorectal Cancer Screening Protocols in Urban Chinese Populations," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-8, October.
  35. C. Armero & G. García‐Donato & A. López‐Quílez, 2010. "Bayesian methods in cost–effectiveness studies: objectivity, computation and other relevant aspects," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 629-643, June.
  36. Franck Maunoury & Aurore Clément & Chizoba Nwankwo & Laurie Levy-Bachelot & Armand Abergel & Vincent Di Martino & Eric Thervet & Isabelle Durand-Zaleski, 2018. "Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France," PLOS ONE, Public Library of Science, vol. 13(3), pages 1-20, March.
  37. Erik Rosenstrom & Sareh Meshkinfam & Julie Simmons Ivy & Shadi Hassani Goodarzi & Muge Capan & Jeanne Huddleston & Santiago Romero-Brufau, 2022. "Optimizing the First Response to Sepsis: An Electronic Health Record-Based Markov Decision Process Model," Decision Analysis, INFORMS, vol. 19(4), pages 265-296, December.
  38. Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter, 2009. "An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 111-119, February.
  39. Gordon B. Hazen, 2022. "Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness," INFORMS Journal on Computing, INFORMS, vol. 34(6), pages 3170-3180, November.
  40. Elena Losina & Elizabeth E Dervan & A David Paltiel & Yan Dong & R John Wright & Kurt P Spindler & Lisa A Mandl & Morgan H Jones & Robert G Marx & Clare E Safran-Norton & Jeffrey N Katz, 2015. "Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-17, June.
  41. Stephen G. Pauker & John B. Wong, 2005. "The Influence of Influence Diagrams in Medicine," Decision Analysis, INFORMS, vol. 2(4), pages 238-244, December.
  42. Steven M. Shechter & Matthew D. Bailey & Andrew J. Schaefer & Mark S. Roberts, 2008. "The Optimal Time to Initiate HIV Therapy Under Ordered Health States," Operations Research, INFORMS, vol. 56(1), pages 20-33, February.
  43. J. Robert Beck, 2001. "Medical Decision Making: 20 Years of Advancing the Field," Medical Decision Making, , vol. 21(1), pages 73-75, February.
  44. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
  45. Peter Lindgren & Martin Buxton & Thomas Kahan & Neil Poulter & Björn Dahlöf & Peter Sever & Hans Wedel & Bengt Jönsson, 2009. "The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone," PharmacoEconomics, Springer, vol. 27(3), pages 221-230, March.
  46. Malek B Hannouf & Chander Sehgal & Jeffrey Q Cao & Joseph D Mocanu & Eric Winquist & Gregory S Zaric, 2012. "Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-9, June.
  47. Julio Emilio Marco-Franco & Pedro Pita-Barros & Silvia González-de-Julián & Iryna Sabat & David Vivas-Consuelo, 2021. "Simplified Mathematical Modelling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain," Mathematics, MDPI, vol. 9(5), pages 1-15, March.
  48. Kokuvi Atsou & Christos Chouaid & Gilles Hejblum, 2011. "Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease," PLOS ONE, Public Library of Science, vol. 6(9), pages 1-9, September.
  49. Hai Chen & Lijun Chen, 2017. "Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-15, April.
  50. Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
  51. Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.
  52. Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson, 2006. "A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy," PharmacoEconomics, Springer, vol. 24(4), pages 387-400, April.
  53. Hua Zhang & Mingdong Huo & Jianqian Chao & Pei Liu, 2016. "Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-9, August.
  54. Mylene Lagarde & John Cairns, 2012. "Modelling human resources policies with Markov models: an illustration with the South African nursing labour market," Health Care Management Science, Springer, vol. 15(3), pages 270-282, September.
  55. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
  56. Bart Heeg & Ron Peters & Marc Botteman & Ben Hout, 2007. "Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 25(9), pages 769-782, September.
  57. Teresa Cardoso & Mónica Oliveira & Ana Barbosa-Póvoa & Stefan Nickel, 2012. "Modeling the demand for long-term care services under uncertain information," Health Care Management Science, Springer, vol. 15(4), pages 385-412, December.
  58. K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
  59. Nick Freemantle & Kristin Khalaf & Clara Loveman & Sanja Stanisic & Dmitry Gultyaev & Johanna Lister & Marcus Drake, 2016. "OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(7), pages 911-921, September.
  60. F. R. Rolli & M. Ruggeri & F. Kheiraoui & C. Drago & M. Basile & C. Favaretti & A. Cicchetti, 2018. "Economic evaluation of Zepatier for the management of HCV in the Italian scenario," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1365-1374, December.
  61. Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
  62. Jessica Thompson & Simon White & Stephen Chapman, 2020. "Virtual patients as a tool for training pre-registration pharmacists and increasing their preparedness to practice: A qualitative study," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-16, August.
  63. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
  64. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
  65. Anna Ringborg & Peter Lindgren & Bengt Jönsson, 2005. "The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 354-362, December.
  66. Nicola J. Cooper & Alex J. Sutton & Keith R. Abrams & David Turner & Allan Wailoo, 2004. "Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 203-226, March.
  67. Anna K. Lugnér & Sido D. Mylius & Jacco Wallinga, 2010. "Dynamic versus static models in cost‐effectiveness analyses of anti‐viral drug therapy to mitigate an influenza pandemic," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 518-531, May.
  68. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
  69. Franck Maunoury & Anastasiia Motrunich & Maria Palka-Santini & Stéphanie F Bernatchez & Stéphane Ruckly & Jean-François Timsit, 2015. "Cost-Effectiveness Analysis of a Transparent Antimicrobial Dressing for Managing Central Venous and Arterial Catheters in Intensive Care Units," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
  70. Vartanov, Sergey & Bogatova, Irina & Denisova, Irina & Kucheryanu, Valerian & Tourdyeva, Natalia & Chubarova, Tatyana & Shakleina, Marina & Polterovich, Victor, 2020. "Экономическая Эффективность Доклинической Диагностики Болезни Паркинсона: Марковская Модель [Cost-effectiveness of preclinical Parkinsonism diagnosis: a Markov model]," MPRA Paper 103096, University Library of Munich, Germany.
  71. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
  72. Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
  73. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
  74. Jagpreet Chhatwal & Oguzhan Alagoz & Elizabeth S. Burnside, 2010. "Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors," Operations Research, INFORMS, vol. 58(6), pages 1577-1591, December.
  75. Jönsson, Linus & Borgström, Fredrik & Zethraeus, Niklas, 2002. "Cost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark - An Economic Evaluation Based on the Fracture Intervention Trial," SSE/EFI Working Paper Series in Economics and Finance 501, Stockholm School of Economics.
  76. K. Claxton & P. J. Neumannn & S. S. Araki & M. C. Weinstein, "undated". "Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's Disease," Discussion Papers 00/39, Department of Economics, University of York.
  77. David P Holland & Gillian D Sanders & Carol D Hamilton & Jason E Stout, 2012. "Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis," PLOS ONE, Public Library of Science, vol. 7(1), pages 1-9, January.
  78. Gandjour, Afschin & Stock, Stephanie, 2007. "A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness," Health Policy, Elsevier, vol. 83(2-3), pages 257-267, October.
  79. Sampson, Christopher & James, Marilyn & Huband, Nick & Geelan, Steve & McMurran, Mary, 2013. "Cost implications of treatment non-completion in a forensic personality disorder service," MPRA Paper 48757, University Library of Munich, Germany.
  80. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
  81. Kaltenthaler, Eva & Tappenden, Paul & Booth, Andrew & Akehurst, Ron, 2008. "Comparing methods for full versus single technology appraisal: A case study of docetaxel and paclitaxel for early breast cancer," Health Policy, Elsevier, vol. 87(3), pages 389-400, September.
  82. Carlo Lazzaro & Cecile van Steen & Florent Aptel & Cedric Schweitzer & Luigi Angelillo, 2022. "Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in Fr," Post-Print hal-03696350, HAL.
  83. Muge Capan & Julie S. Ivy & James R. Wilson & Jeanne M. Huddleston, 2017. "A stochastic model of acute-care decisions based on patient and provider heterogeneity," Health Care Management Science, Springer, vol. 20(2), pages 187-206, June.
  84. Savvas S. Ioannou & Yiola Marcou & Eleni Kakouri & Michael A. Talias, 2020. "Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective," IJERPH, MDPI, vol. 17(12), pages 1-20, June.
  85. Ana P. Johnson-Masotti & Purushottam W. Laud & Raymond G. Hoffmann & Matthew J. Hayat & Steven D. Pinkerton, 2001. "Probabilistic Cost-Effectiveness Analysis of HIV Prevention," Evaluation Review, , vol. 25(4), pages 474-502, August.
  86. Jonathan Karnon & Thomas Delea & Vicki Barghout, 2008. "Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(2), pages 171-183, May.
  87. Jan Jürgensen & Wolfgang Arns & Bastian Haß, 2010. "Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 15-25, February.
  88. Chisholm, Orin & Sharry, Patrick & Phillips, Lawrence, 2022. "Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities," LSE Research Online Documents on Economics 114407, London School of Economics and Political Science, LSE Library.
  89. James Shearer & Colin Green & Carl Counsell & John Zajicek, 2011. "The use of decision-analytic models in Parkinson’s disease," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 243-258, July.
  90. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
  91. Ivan Jeliazkov & Dale J. Poirier, 2007. "Dynamic and Structural Features of Intifada Violence: A Markov Process Approach," Working Papers 070801, University of California-Irvine, Department of Economics.
  92. Office of Health Economics, 1997. "The Pros and Cons of Modelling in Economic Evaluation," Briefing 000428, Office of Health Economics.
  93. Joseph N Jarvis & Thomas S Harrison & Stephen D Lawn & Graeme Meintjes & Robin Wood & Susan Cleary, 2013. "Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa," PLOS ONE, Public Library of Science, vol. 8(7), pages 1-9, July.
  94. Douglas K. Owens, 2002. "Analytic Tools for Public Health Decision Making," Medical Decision Making, , vol. 22(1_suppl), pages 3-10, September.
  95. Stavroula A Chrysanthopoulou, 2017. "MILC: A Microsimulation Model of the Natural History of Lung Cancer," International Journal of Microsimulation, International Microsimulation Association, vol. 10(3), pages 5-26.
  96. Philippe Carette & Marie-Anne Guerry, 2022. "Markov models for duration-dependent transitions: selecting the states using duration values or duration intervals?," Statistical Methods & Applications, Springer;Società Italiana di Statistica, vol. 31(5), pages 1203-1223, December.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.